UK startup George Medicines has named Mark Mallon as its new chief executive, who will oversee the company as it tries to get ...

Johnson & Johnson’s Rybrevant is on the brink of EU approval as a treatment for a subset of patients with newly diagnosed ...

Pfizer has said it will launch its just-approved haemophilia B gene therapy Beqvez with a warranty programme that will ...

For many years, orphan drugs for rare diseases have been a draw for pharma companies, offering high prices, swift regulatory ...

Owlstone Medical has secured a $5 million equity investment and initial $1.5 million grant funding, committed by the Bill and ...

While the details of the deal have remained under wraps, a report from the Wall Street Journal revealed that approximately ...

The San Francisco-based company has emerged from the incubators of ARCH Venture Partners and Foresite Labs with more than $1 ...

At Reuters Pharma USA last month, pharmaphorum editor-in-chief Jonah Comstock caught up with Meruno Perugini, president of ...

Fast forward to 2033, and the number of patients with end stage kidney disease requiring dialysis could increase by nearly ...

The new generative AI (GenAI) develops molecules from scratch in a way that precisely matches the protein they are intended ...

At its heart is a project run by the FDA’s Centre for Devices and Radiological Health (CDRH) to design an AR/VR-enabled ...

The cycle from hot to cold to hot again can take 10-15 years and a new technology may go through more than one such cycle (as ...